An experimental Alzheimer’s drug from Acumen Pharmaceuticals did not slow the decline in memory, thinking and everyday function that the disease brings, the company said on October 30, 2026. The drug, an antibody called sabirnetug, did lower the amount of amyloid plaque seen on brain scans. But because it missed the trial’s main goal, Acumen says it will stop developing it, including the follow-on part of the study1.
The result comes from ALTITUDE-AD, a Phase 2 trial, a mid-sized study meant to show whether a drug is worth testing in a larger, final round2. It enrolled 542 people with early Alzheimer’s disease, meaning mild memory and thinking problems or mild dementia caused by the disease1.
What happened
Volunteers were split at random into three groups. Two groups received sabirnetug at one of two dose levels, and one group received a placebo, a dummy infusion with no drug. The infusions were given into a vein once every four weeks1. The study was double-blind, meaning neither the volunteers nor their doctors knew who was getting what. It ran at sites in the United States, Canada, the European Union and the United Kingdom1.
The main question was whether the drug slowed decline on a combined score of thinking and daily function, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS. According to Acumen, it did not, at either dose, when measured at 18 months1. The trial registry lists the same score as the main goal, measured from the start of the study up to week 802.
A second widely used measure of dementia severity, the Clinical Dementia Rating–Sum of Boxes (CDR-SB), also showed no meaningful difference between either drug group and the placebo group, the company said1. Other key secondary goals did not reach statistical significance either, meaning any differences could have been due to chance1.
“While we are disappointed the trial did not meet its primary endpoint, we express our compassion and hope for future therapeutic options for patients with Alzheimer’s disease and their families,” said Daniel O’Connell, chief executive officer of Acumen1.
What the trial did and did not move
The one clear signal was on brain scans. Amyloid plaque, the sticky protein deposits that build up in the brains of people with Alzheimer’s, was measured with PET scans, a type of imaging that can show plaque in living people. Both dose levels lowered plaque in a statistically significant way at weeks 36 and 76, according to Acumen1.
So the drug changed something in the brain, but by the company’s own account that change did not show up as slower decline in how people thought, remembered or managed daily life. That gap between a change on a scan and a change in how patients feel and function is the core finding of this readout.
On safety, Acumen described sabirnetug as generally well tolerated. About 10% of people who got the drug had ARIA-E, a type of brain swelling that appears on MRI scans and is linked to antibodies that target amyloid1. The company’s summary did not give further detail on how serious those cases were.
What these results do not show yet
These are headline results announced by the company, not a peer-reviewed paper. Psychiatric Times noted that the information released so far did not include P values or effect sizes, the numbers that would show how large any differences between groups were and how likely they were to be real1. Without them, outside experts cannot yet judge whether the drug groups trended slightly better, slightly worse or the same as placebo.
Acumen says it expects more data from the trial in the coming weeks, including fluid biomarkers (proteins measured in blood or spinal fluid) and additional brain imaging. The company says it does not expect those data to change its conclusions about whether the drug worked on its main goals1.
The registry listed the trial’s primary completion as October 2026 and showed no results posted there yet2.
Who is behind it
Acumen Pharmaceuticals is a company based in Newton, Massachusetts, traded on the Nasdaq exchange, and it sponsored and paid for the trial32. All of the results reported so far come from the company. Sabirnetug was its lead product: Acumen has described itself as focused on advancing this one drug3.
The US Food and Drug Administration had given sabirnetug Fast Track designation for early Alzheimer’s, a status meant to speed up the review of drugs for serious conditions1. The Phase 2 trial followed an earlier, smaller first-in-human study called INTERCEPT-AD, which the company described as positive1. That earlier study was published in 2025 in the Journal of Prevention of Alzheimer’s Disease, with Acumen’s chief medical officer, Eric Siemers, as the first author13.
Acumen had also been working on a version of the drug that could be injected under the skin, using a delivery technology from Halozyme, and on a project with JCR Pharmaceuticals to carry an Alzheimer’s therapy across the barrier that protects the brain3. The sources do not say what will happen to those efforts now that sabirnetug’s development is ending.
How it fits the field
Sabirnetug was built to test a specific idea. Rather than going mainly after the large amyloid plaques, it was designed to grab small, floating clumps of amyloid called soluble oligomers. Acumen describes these as a highly toxic form of the protein, more harmful than single amyloid pieces or plaques3. In lab research, these oligomers have been seen to bind to nerve cells, interfere with the connections between them and cause nerve damage, according to the company3. The drug was meant to test whether oligomers are an early and lasting cause of the brain damage in Alzheimer’s1.
The company’s founders pioneered research on these oligomers3, which makes this trial a central test of that line of thinking. The results show that, in this trial and at these doses, targeting oligomers with this antibody lowered plaque on scans but did not slow decline over 18 months. They do not by themselves settle whether oligomers matter in Alzheimer’s, and the full data may help researchers understand why the scan changes did not carry through to symptoms.
The readout landed in a busy week for dementia research. A day earlier, Psychiatric Times reported that a different experimental drug, neflamapimod, missed its main goal in dementia with Lewy bodies, another form of dementia1. Biohack also covered a mouse study this week in which a tuberculosis vaccine cut brain tangles linked to dementia.
What to watch next
- The remaining data. Acumen expects blood, spinal fluid and further imaging results from the trial in the coming weeks1.
- A medical meeting in November. Before the results came out, Acumen had planned three posters at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, November 16-19, 2026. Those were about who joined the trial and the experiences of participants and their care partners, not about whether the drug worked3. Whether the efficacy results will be presented there in more detail has not been announced.
- Full publication. The exact size of any differences between groups, and details on side effects, will only be clear once full results are posted to the registry or published12.
- The company’s next steps. With its lead drug stopped, it is not yet clear from the sources what Acumen will do next with its other programs3.
Biohack reports on research and does not give medical advice. People with questions about Alzheimer’s treatment should talk with their own doctor.
